Zhejiang CONBA Pharmaceutical Co Ltd (600572) - Total Liabilities
Based on the latest financial reports, Zhejiang CONBA Pharmaceutical Co Ltd (600572) has total liabilities worth CN¥2.85 Billion CNY (≈ $417.57 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Zhejiang CONBA Pharmaceutical Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Zhejiang CONBA Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Zhejiang CONBA Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Zhejiang CONBA Pharmaceutical Co Ltd (600572) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Zhejiang CONBA Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang CONBA Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eaglerise Electric & Electronic China Co Ltd Class A
SHE:002922
|
China | CN¥4.61 Billion |
|
Reinsurance Group of America Inc
NYSE:RZB
|
USA | $150.68 Billion |
|
Bestway Marine & Energy Technology Co Ltd
SHE:300008
|
China | CN¥3.30 Billion |
|
Bolsas y Mercados Argentinos SA
BA:BYMA
|
Argentina | AR$1.90 Trillion |
|
Concentrix Corporation
NASDAQ:CNXC
|
USA | $7.89 Billion |
|
Hunan Aihua Group Co Ltd
SHG:603989
|
China | CN¥2.23 Billion |
|
Oil Refineries Ltd.
TA:ORL
|
Israel | ILA2.56 Billion |
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
China | CN¥2.39 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Zhejiang CONBA Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zhejiang CONBA Pharmaceutical Co Ltd (600572) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang CONBA Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang CONBA Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.83 Billion ≈ $414.44 Million |
-5.25% |
| 2024-12-31 | CN¥2.99 Billion ≈ $437.40 Million |
-23.13% |
| 2023-12-31 | CN¥3.89 Billion ≈ $569.02 Million |
+7.84% |
| 2022-12-31 | CN¥3.61 Billion ≈ $527.66 Million |
+6.04% |
| 2021-12-31 | CN¥3.40 Billion ≈ $497.61 Million |
-13.45% |
| 2020-12-31 | CN¥3.93 Billion ≈ $574.96 Million |
-20.10% |
| 2019-12-31 | CN¥4.92 Billion ≈ $719.60 Million |
-0.06% |
| 2018-12-31 | CN¥4.92 Billion ≈ $720.07 Million |
+37.59% |
| 2017-12-31 | CN¥3.58 Billion ≈ $523.36 Million |
-10.74% |
| 2016-12-31 | CN¥4.01 Billion ≈ $586.35 Million |
-19.92% |
| 2015-12-31 | CN¥5.00 Billion ≈ $732.16 Million |
+70.85% |
| 2014-12-31 | CN¥2.93 Billion ≈ $428.55 Million |
+57.26% |
| 2013-12-31 | CN¥1.86 Billion ≈ $272.52 Million |
-11.23% |
| 2012-12-31 | CN¥2.10 Billion ≈ $307.01 Million |
+55.60% |
| 2011-12-31 | CN¥1.35 Billion ≈ $197.30 Million |
+80.42% |
| 2010-12-31 | CN¥747.34 Million ≈ $109.36 Million |
-4.28% |
| 2009-12-31 | CN¥780.76 Million ≈ $114.25 Million |
+20.19% |
| 2008-12-31 | CN¥649.60 Million ≈ $95.06 Million |
-6.31% |
| 2007-12-31 | CN¥693.32 Million ≈ $101.45 Million |
+10.37% |
| 2006-12-31 | CN¥628.20 Million ≈ $91.93 Million |
+12.07% |
| 2005-12-31 | CN¥560.55 Million ≈ $82.03 Million |
+34.63% |
| 2004-12-31 | CN¥416.37 Million ≈ $60.93 Million |
+21.67% |
| 2003-12-31 | CN¥342.22 Million ≈ $50.08 Million |
+30.68% |
| 2002-12-31 | CN¥261.88 Million ≈ $38.32 Million |
-1.45% |
| 2001-12-31 | CN¥265.74 Million ≈ $38.89 Million |
-- |
About Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nut… Read more